



A Novel Heterozygous Mutation in the *STAT1* SH2 Domain Causes Chronic Mucocutaneous Candidiasis, Atypically Diverse Infections, Autoimmunity, and Impaired Cytokine Regulation

OPEN ACCESS

Edited by:

Isabelle Meyts,
KU Leuven, Belgium

Reviewed by:

Smita Y. Patel,
John Radcliffe Hospital, UK
Rik Schrijvers,
KU Leuven, Belgium
Anne Puel,
Institut national de la santé et de la
recherche médicale (INSERM),
France
Marta Rizzi,
University Medical Center Freiburg,
Germany

*Correspondence:

Virgil A. S. H. Dalm
v.dalm@erasmusmc.nl

Specialty section:

This article was submitted to Primary
Immunodeficiencies,
a section of the journal
Frontiers in Immunology

Received: 22 September 2016

Accepted: 24 February 2017

Published: 13 March 2017

Citation:

Meesilpavikkai K, Dik WA, Schrijver B,
Nagtzaam NMA, van Rijswijk A,
Driessen GJ, van der Spek PJ,
van Hagen PM and Dalm VASH
(2017) A Novel Heterozygous
Mutation in the *STAT1* SH2 Domain
Causes Chronic Mucocutaneous
Candidiasis, Atypically Diverse
Infections, Autoimmunity, and
Impaired Cytokine Regulation.
Front. Immunol. 8:274.
doi: 10.3389/fimmu.2017.00274

Kornvalee Meesilpavikkai^{1,2,3}, Willem A. Dik^{1,4}, Benjamin Schrijver^{1,4}, Nicole M. A. Nagtzaam^{1,4},
Angelique van Rijswijk^{1,4}, Gertjan J. Driessen^{1,5}, Peter J. van der Spek⁶, P. Martin van Hagen^{1,2}
and Virgil A. S. H. Dalm^{1,2*}

¹Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Internal Medicine, Division of Clinical Immunology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Faculty of Medicine, Department of Microbiology, Chulalongkorn University, Bangkok, Thailand, ⁴Laboratory Medical Immunology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁵Department of Pediatrics, Division of Infectious Disease and Immunology, Erasmus University Medical Center, Rotterdam, Netherlands, ⁶Department of Bioinformatics, Erasmus University Medical Center, Rotterdam, Netherlands

Chronic mucocutaneous candidiasis (CMC) is a primary immunodeficiency characterized by persistent or recurrent skin and mucosal surface infections with *Candida* species. Different gene mutations leading to CMC have been identified. These include various heterozygous gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (*STAT1*) that are not only associated with infections but also with autoimmune manifestations. Recently, two *STAT1* GOF mutations involving the Src homology 2 (SH2) domain have been reported, while so far, over 50 mutations have been described mainly in the coiled coil and the DNA-binding domains. Here, we present two members of a Dutch family with a novel *STAT1* mutation located in the SH2 domain. T lymphocytes of these patients revealed *STAT1* hyperphosphorylation and higher expression of *STAT1* target genes. The clinical picture of CMC in our patients could be explained by diminished production of interleukin (IL)-17 and IL-22, cytokines important in the protection against fungal infections.


Keywords: chronic mucocutaneous candidiasis, signal transducer and activator of transcription 1, Src homology 2 domain, heterozygous mutation, gain-of-function mutation

Abbreviations: CMC, chronic mucocutaneous candidiasis; anti-dsDNA, anti-double stranded DNA; *STAT1*, signal transducer and activator of transcription 1; SH2, Src homology 2; CMV, cytomegalovirus; ANA, antinuclear antibodies; SSA, Sjögren's-syndrome-related antigen A (Ro); CENP-B, centromere protein B; MFI, mean fluorescence intensity; PBMC, peripheral blood mononuclear cells; ELISA, enzyme-linked immunosorbent assay; HKCA, heat-killed *Candida albicans*; PMA, phorbol 12-myristate 13-acetate; I, ionomycin; qRT-PCR, quantitative reverse transcription polymerase chain reaction.

INTRODUCTION

Patient 1 (II-4) (**Figures 1A,B**) is a 24-year-old female who presented at age of 1 with a *Streptococcus haemolyticus* jaw abscess, with recurrent oral and esophageal *Candida albicans* infections from the age of 6 onward and an episode of *Staphylococcus aureus* pneumonia and cytomegalovirus (CMV) pneumonia at age of 7 years. At age of 8, she developed hypothyroidism, and there were serologic signs of celiac disease, without clinical relevance.

Moreover, additional immunological analysis revealed the presence of antinuclear antibodies (ANA) in high titer (1:5,120), anti-Sjögren's-syndrome-related antigen A (Ro), and anti-centromere protein B autoantibodies (anti-CENP-B). At the age of 20, she developed autoimmune hemolytic anemia. Over the past years, the clinical picture has been dominated by recurrent oral and esophageal *C. albicans* infections for which she was repetitively treated with antifungal therapies. To prevent recurrence of *C. albicans* infections, she is currently treated with prophylactic



antifungal therapy (fluconazole 200 mg once daily). Moreover, she has experienced oral and vaginal ulcers which were found negative for bacterial, fungal, and viral microbes as determined by culture and/or PCR of oral and vaginal swabs and tissue biopsies from vaginal ulcers. Because of these ulcers, which were assumed to be autoimmune manifestations related to chronic mucocutaneous candidiasis (CMC), various immunosuppressive therapies have been initiated over time, including steroids, azathioprine, hydroxychloroquine, and mycophenolate mofetil, all with little benefit. She has recently started treatment with adalimumab [anti-tumor necrosis factor (TNF)- α] 40 mg every other week, which resulted in complete resolution of oral and vaginal ulcers after three subcutaneous injections. After three months of treatment, there is still no recurrence of oral and/or vaginal ulcers, whereas no increased incidence of infectious complications was reported while using anti-TNF- α treatment.

Peripheral blood total CD3+ T lymphocyte numbers [$1.63 \times 10^9/l$ (reference value: $0.7\text{--}2.1 \times 10^9/l$)], CD4+ T lymphocyte numbers [$0.6 \times 10^9/l$ (reference value: $0.3\text{--}1.4 \times 10^9/l$)], CD8+ T lymphocyte numbers [$0.84 \times 10^9/l$ (reference value: $0.2\text{--}0.9 \times 10^9/l$)], total CD19+ B lymphocyte numbers [$0.16 \times 10^9/l$ (reference value: $0.1\text{--}0.4 \times 10^9/l$)], and CD16+ CD56+ NK cell numbers [$0.1 \times 10^9/l$ (reference value: $0.1\text{--}0.4 \times 10^9/l$)] were within the normal reference ranges. Immunoglobulin levels were also found to be within normal limits [IgG 10.5 g/l (reference value: 7.0–16.0 g/l), IgA 1.24 g/l (reference value: 0.76–3.91 g/l), and IgM 1.12 g/l (reference value: 0.45–2.30 g/l)]. The patient was negative for autoantibodies against interleukin (IL)-17A, IL-17F, and IL-22. After immunization with a polysaccharide vaccine against *Streptococcus pneumoniae* (Pneumovax), IgG antibody concentration to all 16 serotypes (1, 3, 4, 5, 6B, 7F, 8, 9V, 14, 15B, 18C, 19A, 19F, 20, 23F, and 33F) measured increased when compared to pre-vaccination concentrations and for 12 serotypes the post-immunization concentrations reached values above 1 $\mu\text{g/ml}$, which is indicative of a normal response to polysaccharide immunization (1).


Patient 2 (I-1) (Figures 1A,B) is the 50-year-old father of patient 1, with a medical history including aortic valve replacement at age 29 and surgical and antibiotic treatment for a culture-negative, frontal-lobe brain abscess at age 33. He presented for the first time at our outpatient clinic at the age of 49 because of very severe *C. albicans* infection in the oral cavity and esophagus. At that time, he had already suffered from recurrent oral and esophageal fungal infections for years, for which he was treated with antifungal therapies by his general physician. Microbiological analysis revealed a fluconazole-resistant *C. albicans* and treatment with posaconazole 400 mg once daily was initiated with prompt clinical improvement. Subsequently, prophylactic posaconazole 200 mg once daily has been prescribed. At the time of first analysis, also autoimmune hypothyroidism with positivity for antithyroglobulin antibodies, ANA and lupus anticoagulant were detected. Peripheral blood total CD3+ T lymphocyte numbers [$1.06 \times 10^9/l$ (reference value: $0.7\text{--}2.1 \times 10^9/l$)], CD4+ T lymphocyte numbers [$0.5 \times 10^9/l$ (reference value: $0.3\text{--}1.4 \times 10^9/l$)], CD8+ T lymphocyte numbers [$0.52 \times 10^9/l$ (reference value: $0.2\text{--}0.9 \times 10^9/l$)], total CD19+ B lymphocyte numbers [$0.35 \times 10^9/l$ (reference value: $0.1\text{--}0.4 \times 10^9/l$)], and CD16+ CD56+ NK cell numbers

[$0.16 \times 10^9/l$ (reference value: $0.1\text{--}0.4 \times 10^9/l$)] were within the normal reference range. Immunoglobulin levels were also found within normal limits [IgG 12.9 g/l (reference value: 7.0–16.0 g/l), IgA 1.65 g/l (reference value: 0.76–3.91 g/l), and IgM 0.8 g/l (reference value: 0.45–2.30 g/l)]. The patient was negative for autoantibodies against IL-17A, IL-17F, and IL-22.

Sanger sequencing from all affected individuals in the family revealed a novel heterozygous *signal transducer and activator of transcription 1 (STAT1)* mutation in exon 22 at c.1957G>A, while genetic testing for mutations in 276 other known genes involved in primary immunodeficiency was negative (Table S1 in Supplementary Material). The nucleotide base change we identified has not been reported as single nucleotide polymorphism (the Human Gene Mutation Database, the National Center of Biotechnology Information, the ExAC database, the 1000G database, and the Ensembl database). The identified mutation results in replacement of a highly conserved valine at position 653 (vertebrate PhyloP100 score 3.798 and SiPhy score 19.656) (Figures 1C,D; Table S2 in Supplementary Material) into isoleucine [p.(Val653Ile)] within the Src homology 2 (SH2) domain of STAT1. The mutation is exposed on the outer surface of the molecule and within the vicinity of the phosphorylation site (Figure 1E; Video S1 in Supplementary Material). The Val653Ile mutation is predicted to hardly affect the overall structure of STAT1 and was predicted as “tolerated” by the Sort Intolerant From Tolerant algorithm (score 0.58). However, Val653Ile was predicted as “possibly damaging” by the Polymorphism Phenotyping v2 (PolyPhen-2, score 0.919), the mutation was speculated as “disease causing” from the Mutation Taster and was scaled in Combined Annotation Dependent Depletion algorithm with a score of 14.99, which suggests potential deleteriousness.

To evaluate the immunological phenotype associated with this mutation, STAT1 phosphorylation was studied by flow cytometry of fresh whole blood samples from patient 1 and an age-gender-race-matched healthy control. After stimulation with interferon (IFN)- α (10^4 IU/ml; PeproTech, London, UK), IFN- β (10^3 IU/ml; tebu-bio, Le-Perray-en-Yvelines, France), IFN- γ (10^5 IU/ml; R&D systems, Abingdon, UK) for 30 min, or IL-6 (100 ng/ml; R&D systems) for 15 min, cells were fixed and permeabilized with permeabilizing reagent (Phospho-Epitopes Exposure kit; Beckman Coulter). All samples were stained with CD3 (APC-conjugated antihuman CD3; BD Biosciences, CA, USA) and Fluor[®] 488-conjugated phospho-STAT1 Tyr701 antibodies (Cell Signaling Technology, MA, USA). The levels of STAT1 phosphorylation in the CD3+ T lymphocytes from the patient were higher than the levels observed in the healthy control after stimulation with IFNs (Figure 2A) or IL-6 (data not shown). To study the kinetics of STAT1 phosphorylation in more detail, time-course stimulation experiments were performed with fresh whole blood samples from patients 1 and 2 along with age-gender-race-matched healthy controls. The patients clearly displayed higher levels of STAT1 phosphorylation, yet the phosphorylation levels of both the patients and controls normalized over time (Figure 2B).

Because we found a higher basal level of phosphorylated STAT1 (pSTAT1) in patient 1 (Figure S1 in Supplementary Material), we established T lymphocyte cultures to reduce the



confounding effects of exposure of both patients to different pathogens and therapies. Long-term T lymphocyte cultures were expanded from peripheral blood mononuclear cells (PBMC) of both patients and two age-gender-race-matched healthy controls

in RPMI-1640 medium (Lonza, Basel, Switzerland), containing 10% heat inactivated human serum and antibiotics (2% penicillin and streptomycin; Cambrex BioWhittaker, Verviers, Belgium) in the presence of Phytohemagglutinin (1 μg/ml; Sigma-Aldrich,

MO, USA), IL-2 (25 IU/ml; Novartis, Basel, Switzerland), IL-15 (12.5 ng/ml; BioLegend, CA, USA), and γ -irradiated (40 Gy) allogeneic PBMC and EBV-negative B lymphocytes. After 2 weeks of culturing, T lymphocyte cultures (purity >90%) from both patients and healthy controls were analyzed for *STAT1* phosphorylation in a manner similar to the whole blood samples. IFN stimulation resulted in higher generation of p*STAT1* in the T lymphocyte cultures from patients compared to healthy controls (**Figure 2C**). Stimulation of T lymphocyte cultures with IL-6 (100 ng/ml) yielded comparable results on p*STAT1* as IFN- γ (data not shown). T lymphocytes from the patients and healthy controls displayed similar levels of total *STAT1* protein [determined by flow cytometry using a PE-conjugated *STAT1* antibody (BD Biosciences; data not shown)]. *STAT3* phosphorylation was also evaluated after stimulation with IL-6 (100 ng/ml) or IL-21 (200 ng/ml; Life Technologies, MA, USA) but did not differ between patients and healthy controls (data not shown).

To assess the effect of the *STAT1* mutation on cytokine production, PBMC of both patients and five race-matched healthy controls were freshly prepared and stimulated with heat-killed *C. albicans* [heat-killed *Candida albicans* (HKCA): 10^6 cells]. Supernatants were collected, and levels of cytokines were measured by enzyme-linked immunosorbent assay (R&D systems). Cells were also stimulated with phorbol 12-myristate 13-acetate (PMA) (81 nM) and ionomycin (I) (1.3 μ M; eBioscience, CA, USA) as positive control. PBMC from both patients produced IL-6 and IL-1 β levels comparable to that of healthy controls, while PBMC from patient 1 did not produce IFN- γ when stimulated with HKCA (**Figure 3A**). In contrast to PBMC from healthy controls, PBMC from the patients hardly increased IL-17A, IL-17F, and IL-22 production upon stimulation with PMA-I or HKCA (**Figure 3A**). *STAT1* downstream target genes were also measured in T lymphocyte cultures. Due to limited T lymphocyte numbers in these cultures, only one time-point of stimulation (24 h) with three different stimuli [IFN- γ (10^5 IU/ml), IL-6 (100 ng/ml), and IL-27 (200 ng/ml; R&D systems)] was examined. *CXCL9*, *CXCL10*, and *CD274* (PD-L1) mRNA expression levels were determined by real-time quantitative Taqman PCR in each sample on the basis of six replicates. Strikingly high mRNA levels were observed after IL-27 activation ($P < 0.001$) (**Figure 3B**).

BACKGROUND

Chronic and/or recurrent fungal infections may be predominant manifestations in primary immunodeficiencies, especially in inherited T lymphocyte defects. Various syndromes have been identified that present with recurrent fungal infections, for example, autosomal dominant (AD) hyper-immunoglobulin E syndrome, autosomal recessive autoimmune polyendocrine syndrome type I, and Mendelian susceptibility to mycobacterial diseases. AD-CMC is a rare and severe immunodeficiency that presents with severe mucocutaneous fungal infections, autoimmune phenomena, cerebral aneurysms and increased risk of oropharyngeal, and esophageal cancer (2–4). In the last decade, various heterozygous gain-of-function (GOF) mutations in *STAT1* were found to be responsible for AD-CMC. So far, GOF


mutations were described in the coiled-coil domain and the DNA-binding domain of *STAT1*, and in the past year, the GOF mutations c.1885C>T (p.H629Y) and c.1973G>A (p.N658S) involving the SH2 domain were described (5–7). Chronic and/or recurrent mucocutaneous fungal infections with predominantly *C. albicans* are the major infectious complications in patients with *STAT1* GOF mutations and generally arise in infancy or childhood. However, more than half of the patients encounter bacterial infections, with lower respiratory tract infections most frequently observed. Cutaneous viral infections are also described in about one third of patients (6, 8). In addition, many patients with GOF mutations in *STAT1* develop autoimmune manifestations. Autoimmune thyroid disease is reported in 22% of patients. Cerebral aneurysms and cancers are among the most severe complications that are found more frequently and at younger age in these patients when compared to the general population (6, 8).

DISCUSSION

The mutation identified in our patients is located in the *STAT1* SH2 domain resulting in recurrent mucocutaneous *C. albicans* infections, which is one of the clinical hallmarks of CMC. The other two family members who carry the same *STAT1* mutation but were not included in this study also suffered from recurrent mucocutaneous candidiasis (**Figure 1B**). In addition to fungal infections, patient 1 showed an atypical susceptibility to a wide range of pathogens, as she experienced *S. haemolyticus* jaw abscess, *S. aureus* pneumonia, and CMV pneumonia. Lower respiratory tract bacterial infections can be found in about half of patients with *STAT1* GOF mutations. However, based on previous reports, CMV pneumonia was described in only 1% of patients. Patient 2 also encountered an intracranial abscess for which surgical and antibiotic treatments were required. Although the pathogenic microorganism could not be isolated, invasive deep-seated abscesses are uncommon for patients with *STAT1* GOF mutations (6). Apart from CMC, atypical features of infections including invasive bacterial infections were also described in other patients carrying a *STAT1* GOF mutation in the SH2 domain (5–7). Both patients 1 and 2 enrolled in this study developed a variety of autoimmune phenomena that were displayed in both clinical and laboratory analyses.

In response to various kinds of infections, *STAT1* receives signals from the cell surface receptors and is subsequently phosphorylated at Tyr701. The SH2 domain carries the pTyr701-binding site and accordingly plays an important role in forming a firm cross-linkage dimerization between each *STAT1* monomer. The dimers then accumulate in the nucleus, inducing transcription of genes (9). The mutation here described within the SH2 domain of *STAT1* results in enhancement of *STAT1* phosphorylation both upon stimulation with IFN- α/β and IFN- γ , despite the suggestion that the SH2 domain may not necessarily be required for *STAT1* activation by IFN- α/β (10). Moreover, this mutation may possibly affect molecule dimerization due to its specific location within the *STAT1* molecule.

We performed *STAT* phosphorylation analysis of both patients by flow cytometry, which revealed enhancement of



STAT1 phosphorylation, while total *STAT1* protein was equally measured in T lymphocytes of both patients and healthy controls. After stimulation with cytokines, *STAT1* phosphorylation in the T lymphocytes of both patients reached higher levels compared to the healthy controls. In contrast to previous reports studying mutations in other *STAT1* domains (11–13), we found no clear prolonged *STAT1* phosphorylation in the T lymphocytes from the patients. The difference in the mutated domain of *STAT1* could possibly be the cause of different phosphorylation characteristics. Apart from elevated p*STAT1* induction, we

also noticed a higher basal p*STAT1* level in peripheral blood T lymphocytes from patient 1. Stimulation of fresh whole blood from patient 2 yielded comparable results, although this patient showed no elevated basal level of p*STAT1* when compared to healthy controls. However, after re-evaluation in established T lymphocyte cultures, the elevated basal p*STAT1* level previously noted in the whole blood analysis of patient 1 disappeared. Due to the fact that patient 2 received prophylactic antifungal therapy while patient 1 did not at the time of analysis, recurrent exposure of patient 1 to *Candida* antigens could have caused the

elevated basal *STAT1* phosphorylation we observed in her whole blood analysis. Because dysregulation of *STAT3* has also been associated with CMC, we evaluated *STAT3* phosphorylation as well, but this was comparable between the patients and healthy controls.

Th17-derived cytokines are crucial in fungal defense mechanisms (14, 15), and therefore, we examined the cytokine production capacity of PBMC of both patients as well as healthy controls upon activation with HKCA. A remarkable impairment in IL-17A, IL-17E, and IL-22 production was found in the patients. In order to further examine the consequence of this novel *STAT1* SH2 domain mutation, *STAT1* downstream target genes were assessed. T lymphocyte cultures from both patients and healthy controls were stimulated with IFN- γ , IL-6, and IL-27. Significantly higher mRNA levels of *STAT1* downstream target genes were found in both patients, especially upon IL-27 activation, including *CD274* (PD-L1). Overexpression of PD-L1 was previously observed in naïve T lymphocytes of patients with *STAT1* GOF mutation, and cytokine-induced PD-L1 expression in T lymphocytes was found to hamper Th17 induction (16, 17). Our data suggest that disturbed Th17 differentiation and associated cytokine production most likely underlies the clinical picture of CMC in the patients described here.

Since curative treatment is still unavailable, most of the patients with *STAT1* GOF mutations receive prolonged systemic antimicrobial medications to control clinical symptoms of recurrent fungal infections and other infections. Similar to patient 2, about 40% of the patients who require long-term antifungal treatment, eventually develop therapy resistance (6). Immunotherapies or immunosuppressive therapies are considered in some patients, although the effectiveness still needs to be evaluated in more detail (18). Surprisingly, novel therapies, like JAK1/2 inhibitors, showed not only the potency to suppress the enhanced *STAT1* phosphorylation in CD4+ T lymphocytes but may also improve clinical outcome in both immunodeficiency and autoimmunity features (13, 19). These drugs could be potential future candidates for the treatment of patients with CMC with *STAT1* GOF mutations.

REFERENCES

1. Orange JS, Ballou M, Stiehm ER, Ballas ZK, Chinen J, De La Morena M, et al. Use and interpretation of diagnostic vaccination in primary immunodeficiency: a working group report of the Basic and Clinical Immunology Interest Section of the American Academy of Allergy, Asthma & Immunology. *J Allergy Clin Immunol* (2012) 130(3 Suppl):S1–24. doi:10.1016/j.jaci.2012.07.002
2. van de Veerdonk FL, Plantinga TS, Hoischen A, Smeekens SP, Joosten LA, Gilissen C, et al. *STAT1* mutations in autosomal dominant chronic mucocutaneous candidiasis. *N Engl J Med* (2011) 365(1):54–61. doi:10.1056/NEJMoa1100102
3. Liu L, Okada S, Kong XF, Kreinsen AY, Cypowyj S, Abhyankar A, et al. Gain-of-function human *STAT1* mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. *J Exp Med* (2011) 208(8):1635–48. doi:10.1084/jem.20110958
4. Soltész B, Toth B, Shabashova N, Bondarenko A, Okada S, Cypowyj S, et al. New and recurrent gain-of-function *STAT1* mutations in patients with chronic mucocutaneous candidiasis from Eastern and Central Europe. *J Med Genet* (2013) 50(9):567–78. doi:10.1136/jmedgenet-2013-101570

CONCLUDING REMARKS

The novel Val653Ile mutation, located in the SH2 domain of *STAT1* found in this family does not clearly result in an impaired *STAT1* dephosphorylation rate, as was found in patients with GOF mutations in the other domains. However, significantly enhanced *STAT1* phosphorylation in these patients results in higher expression of the *STAT1* target genes *CXCL9*, *CXCL10*, and *CD274* (PD-L1). Moreover, this mutation is associated with the impairment of immune cells to produce IL-17A, IL-17E, and IL-22. The clinical symptoms of CMC could, therefore, be explained by diminished Th17 responses that are crucial for confronting fungal antigens.

ETHICS STATEMENT

This study was approved by the Medical Ethics Committees of Erasmus MC with ethics approval number MEC 2013-026. Clinical data and blood samples of patients with novel *STAT1* mutation and healthy controls were collected after written informed consent was obtained.

AUTHOR CONTRIBUTIONS

KM, WD, PH, and VD designed the research. KM, BS, NN, and AR performed the experiments. KM, WD, PS, and VD analyzed the results. KM, WD, GD, PS, PH, and VD wrote the article.

FUNDING

This research was supported by Erasmus University Medical Center, Rotterdam, The Netherlands and Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at <http://journal.frontiersin.org/article/10.3389/fimmu.2017.00274/full#supplementary-material>.

5. Sobh A, Chou J, Schneider L, Geha RS, Massaad MJ. Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances *STAT1* phosphorylation. *J Allergy Clin Immunol* (2016) 138(1):297–9. doi:10.1016/j.jaci.2015.12.1320
6. Toubiana J, Okada S, Hiller J, Oleastro M, Lagos Gomez M, Aldave Becerra JC, et al. Heterozygous *STAT1* gain-of-function mutations underlie an unexpectedly broad clinical phenotype. *Blood* (2016) 127(25):3154–64. doi:10.1182/blood-2015-11-679902
7. Martínez de Saavedra Álvarez MT, Sologuren Marrero I, Martínez Martínez L, González Quevedo N, Florido Ortega Y, García Martínez JM, et al., editors. Clinical, genetic and immunological variability of chronic mucocutaneous candidiasis due to novel mutations in *Stat1* in six patients from three kindred. 39 *Congreso de la Sociedad Española de Inmunología, May 5-7, 2016*. Alicante (2016).
8. Lorenzini T, Dotta L, Giacomelli M, Vairo D, Badolato R. *STAT* mutations as program switchers: turning primary immunodeficiencies into autoimmune diseases. *J Leukoc Biol* (2017) 101(1):29–38. doi:10.1189/jlb.5R10516-237RR
9. Mao X, Ren Z, Parker GN, Sondermann H, Pastorello MA, Wang W, et al. Structural bases of unphosphorylated *STAT1* association and receptor binding. *Mol Cell* (2005) 17(6):761–71. doi:10.1016/j.molcel.2005.02.021

10. Mowen K, David M. Role of the STAT1-SH2 domain and STAT2 in the activation and nuclear translocation of STAT1. *J Biol Chem* (1998) 273(46):30073–6. doi:10.1074/jbc.273.46.30073
11. Zheng J, van de Veerdonk FL, Crossland KL, Smeekens SP, Chan CM, Al Shehri T, et al. Gain-of-function STAT1 mutations impair STAT3 activity in patients with chronic mucocutaneous candidiasis (CMC). *Eur J Immunol* (2015) 45(10):2834–46. doi:10.1002/eji.201445344
12. Uzel G, Sampaio EP, Lawrence MG, Hsu AP, Hackett M, Dorsey MJ, et al. Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. *J Allergy Clin Immunol* (2013) 131(6):1611–23. doi:10.1016/j.jaci.2012.11.054
13. Baris S, Alroqi F, Kiykim A, Karakoc-Aydiner E, Ogulur I, Ozen A, et al. Severe early-onset combined immunodeficiency due to heterozygous gain-of-function mutations in STAT1. *J Clin Immunol* (2016) 36(7):641–8. doi:10.1007/s10875-016-0312-3
14. Khader SA, Gaffen SL, Kolls JK. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa. *Mucosal Immunol* (2009) 2(5):403–11. doi:10.1038/mi.2009.100
15. Netea MG, Joosten LA, van der Meer JW, Kullberg BJ, van de Veerdonk FL. Immune defence against *Candida* fungal infections. *Nat Rev Immunol* (2015) 15(10):630–42. doi:10.1038/nri3897
16. Romberg N, Morbach H, Lawrence MG, Kim S, Kang I, Holland SM, et al. Gain-of-function STAT1 mutations are associated with PD-L1 overexpression and a defect in B-cell survival. *J Allergy Clin Immunol* (2013) 131(6):1691–3. doi:10.1016/j.jaci.2013.01.004
17. Hirahara K, Ghoreschi K, Yang X-P, Takahashi H, Laurence A, Vahedi G, et al. Interleukin-27 priming of T cells controls IL-17 production in trans via induction of the ligand PD-L1. *Immunity* (2012) 36(6):1017–30. doi:10.1016/j.immuni.2012.03.024
18. van de Veerdonk FL, Netea MG. Treatment options for chronic mucocutaneous candidiasis. *J Infect* (2016) 72(Suppl):S56–60. doi:10.1016/j.jinf.2016.04.023
19. Higgins E, Al Shehri T, McAleer MA, Conlon N, Feighery C, Lilic D, et al. Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. *J Allergy Clin Immunol* (2015) 135(2):551–3. doi:10.1016/j.jaci.2014.12.1867

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The reviewer RS and handling editor declared their shared affiliation, and the handling editor states that the process nevertheless met the standards of a fair and objective review.

Copyright © 2017 Meesilpavikkai, Dik, Schrijver, Nagtzaam, van Rijswijk, Driessen, van der Spek, van Hagen and Dalm. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.